Journals / Cukurova Medical Journal / 2022 / Cilt: 47 - Sayı: 2

Otoprotective effects of farnesene against oxidative damage induced by paclitaxel

Paklitakselin neden olduğu oksidatif hasara karşı farnesenin otoprotektif etkileri

Pages
783–791
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: This study explores the biochemical and functional effects of farnesene, which has potent free radical scavenging and antioxidant properties, on paclitaxel-induced ototoxicity.
📊
Key Findings & Data:Paclitaxel was given four times intraperitoneally at a dose of 5 mg/kg (1st, 7th, 14th & 21st days) in the paclitaxel group.
💡
Conclusion & Impact:Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: This study explores the biochemical and functional effects of farnesene, which has potent free radical scavenging and antioxidant properties, on paclitaxel-induced ototoxicity. Materials and Methods: Eighteen male Wistar albino rats were allocated into three groups of six rats at random. No paclitaxel or farnesene was given to the control group throughout the research. Paclitaxel was given four times intraperitoneally at a dose of 5 mg/kg (1st, 7th, 14th & 21st days) in the paclitaxel group. In the Farnesene + Paclitaxel group, 5 mg/kg paclitaxel was given first, followed by 4 times 50 mg/kg farnesene intraperitoneally 30 minutes later (1st, 7th, 14th & 21st days). Otoacoustic emission measurement was taken on days 0 and 21 in all rats. After that, the animals were sacrificed, and their cochleas were extracted for biochemical testing. Results: Paclitaxel caused oxidative stress in the cochlea, which considerably elevated malondialdehyde levels and lowered glutathione levels in cochlear tissues. Furthermore, the paclitaxel group’s distortion product otoacoustic emission values were significantly lower than the other groups. Improvements in the damage produced by paclitaxel in various biochemical and functional parameters were observed in the Farnesene+Paclitaxel group. Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.

Özet

Amaç: Bu çalışmanın amacı, güçlü serbest radikal süpürücü ve antioksidan özelliklere sahip farnesenin paklitaksel kaynaklı ototoksisite üzerindeki etkilerini biyokimyasal ve fonksiyonel yönden araştırmaktır. Gereç ve Yöntem: On sekiz erkek Wistar albino sıçan, altı sıçandan oluşan üç gruba rastgele ayrıldı. Araştırma boyunca kontrol grubuna paklitaksel veya farnesen verilmedi. Paklitaksel grubuna, 5mg/kg paklitaksel intraperitoneal olarak dört kez (1., 7., 14. ve 21. günlerde) verildi. Farnesen + paklitaksel grubuna, önce 5 mg/kg paklitaksel, 30 dakika sonra 50 mg/kg farnesen intraperitoneal olarak 4 kez (1., 7., 14. ve 21. günlerde) verildi. 0. ve 21. günlerde tüm sıçanların otoakustik emisyon ölçümü yapıldı. Daha sonra hayvanlar sakrifiye edildi ve biyokimyasal testler için kokleaları çıkarıldı. Bulgular: Paklitaksel, önemli ölçüde malondialdehit seviyelerini yükselterek ve glutatyon seviyelerini düşürerek kokleada oksidatif strese neden oldu. Ayrıca paklitaksel grubunun distorsiyon ürünü otoakustik emisyon değerleri diğer gruplara göre anlamlı derecede düşüktü. Farnesen+paklitaksel grubunda ise paklitakselin çeşitli biyokimyasal ve fonksiyonel parametrelerde oluşturduğu hasarda iyileşmeler gözlendi. Sonuç: Çalışma sonuçları doğal bir antioksidan olan farnesen’in sıçanlarda paklitaksel kaynaklı işitme kaybını azalttığını, farnesen ve paklitaksel kombinasyonunun gelecekte klinik kullanım için paklitaksel kaynaklı ototoksisiteden koruyabileceğini göstermektedir.

🔖

Cite This Article

DİNÇER, B., TATAR, A., ATALAY, F. (2022). Otoprotective effects of farnesene against oxidative damage induced by paclitaxel. Cukurova Medical Journal, Cilt: 47 - Sayı: 2, 783–791. https://ajindex.com/articles/476683

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Lanvers‐Kaminsky C, Zehnhoff‐Dinnesen AM, Parfitt R, Ciarimboli G. Drug‐induced ototoxicity: Mechanisms, pharmacogenetics, and protective strategies. Clin Pharmacol Ther. 2017;101:491-500
  2. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1809394
  3. Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-96
  4. Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N et al. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer. 2012;106:1967-75
  5. Bachegowda LS, Makower DF, Sparano JA. Taxanes: Impact on breast cancer therapy. Anticancer Drugs. 2014;25:512-21
  6. Sakai H, Yoneda S, Tamura T, Nishiwaki Y, Yokoyama A, Watanabe K et al. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients. Cancer Chemother Pharmacol. 2001;48:499-503
  7. Misiukiewicz K, Gupta V, Bakst R,Posner M. Taxanes in cancer of the head and neck. Anticancer Drugs. 2014;25:561-70
  8. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677-81
  9. Park SB, Lin CSY, Krishnan AV, Friedlander ML, Lewis CR, Kiernan MC. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel‐induced neuropathy. Muscle Nerve. 2011;43:367-74
  10. Pace A, Nisticò C, Cuppone F, Bria E, Galiè E, Graziano G et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer. 2007;7:550-4
  11. Dong Y, Ding D, Jiang H, Shi J-r, Salvi R, Roth JA. Ototoxicity of paclitaxel in rat cochlear organotypic cultures. Toxicol Appl Pharmacol. 2014;280:526-33
  12. Sarafraz M, Ahmadi K. Paraclinical evaluation of sideeffects of Taxanes on the auditory system. Acta Otorhinolaryngol Ital. 2008;28:239-42
  13. Tibaldi C, Pazzagli I, Berrettini S,De Vito A. A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine. Eur J Cancer. 1998;34:1133-4
  14. Bucak A, Ozdemir C, Ulu S, Gonul Y, Aycicek A, Uysal M et al. Investigation of protective role of curcumin against paclitaxel‐induced inner ear damage in rats. Laryngoscope. 2015;125:1175-82
  15. Atalay F, Ta